05/03/2024
6:30 AM | Lantern Pharma (Filer)
| Form ARS | |
04/29/2024
6:30 AM | Lantern Pharma (Filer)
| Form DEF 14A | |
04/26/2024
8:36 PM | BIOS Fund I, LP (Reporting)
Lantern Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024
8:38 PM | BIOS Fund I QP, LP (Reporting)
Lantern Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024
8:39 PM | BIOS Fund II, LP (Reporting)
Lantern Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024
8:40 PM | BIOS Fund II QP, LP (Reporting)
Lantern Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024
8:41 PM | BIOS Fund II NT, LP (Reporting)
Lantern Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/29/2024
8:54 PM | BP Directors, LP (Reporting)
Cavu Advisors, LLC (Reporting)
Cavu Management, LP (Reporting)
Kreis Leslie W. (Reporting)
Lantern Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
8:54 PM | BIOS Advisors GP, LLC (Reporting)
BIOS Capital Management, LP (Reporting)
Bios Equity Partners II, LP (Reporting)
Bios Equity Partners, LP (Reporting)
BIOS Fund I QP, LP (Reporting)
BIOS Fund I, LP (Reporting)
BIOS Fund II NT, LP (Reporting)
BIOS Fund II QP, LP (Reporting)
BIOS Fund II, LP (Reporting)
Fletcher Aaron G.L. (Reporting)
Lantern Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/28/2024
8:40 PM | BIOS Fund II, LP (Reporting)
Lantern Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/28/2024
8:41 PM | BIOS Fund II NT, LP (Reporting)
Lantern Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/28/2024
8:41 PM | BIOS Fund II QP, LP (Reporting)
Lantern Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/19/2024
3:30 PM | BP Directors, LP (Reporting)
Cavu Advisors, LLC (Reporting)
Cavu Management, LP (Reporting)
Kreis Leslie W. (Reporting)
Lantern Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/19/2024
3:31 PM | BIOS Advisors GP, LLC (Reporting)
BIOS Capital Management, LP (Reporting)
Bios Equity Partners II, LP (Reporting)
Bios Equity Partners, LP (Reporting)
BIOS Fund I QP, LP (Reporting)
BIOS Fund I, LP (Reporting)
BIOS Fund II NT, LP (Reporting)
BIOS Fund II QP, LP (Reporting)
BIOS Fund II, LP (Reporting)
Fletcher Aaron G.L. (Reporting)
Lantern Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/01/2023
5:00 AM | BP Directors, LP (Reporting)
Cavu Advisors, LLC (Reporting)
Cavu Management, LP (Reporting)
Kreis Leslie W. (Reporting)
Lantern Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/01/2023
5:01 AM | BIOS Advisors GP, LLC (Reporting)
BIOS Capital Management, LP (Reporting)
Bios Equity Partners II, LP (Reporting)
Bios Equity Partners, LP (Reporting)
BIOS Fund I QP, LP (Reporting)
BIOS Fund I, LP (Reporting)
BIOS Fund II NT, LP (Reporting)
BIOS Fund II QP, LP (Reporting)
BIOS Fund II, LP (Reporting)
Fletcher Aaron G.L. (Reporting)
Lantern Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/01/2023
5:02 AM | Bios Equity Partners, LP (Filed by)
Lantern Pharma (Subject)
| Form SC 13D/A | |
11/24/2023
3:05 PM | Lantern Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/20/2023
4:25 PM | Lantern Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/21/2023
3:05 PM | Lantern Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
